RBC Capital analyst Brian Abrahams initiates coverage on Dermata Therapeutics In (NASDAQ: DRMA) with a Outperform rating and a price ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage